Dual-targeted therapy with Certolizumab and Risankizumab for the treatment of Crohn's disease and spondylarthritis

Authors
Category Primary study
JournalSwiss Medical Weekly
Year 2023
This article has no abstract
Epistemonikos ID: 0a1741c58e0d7a8f580f99a507195c23e8cfef6f
First added on: Feb 16, 2025